Galamidi Einat
Transaction: 03/18/2026
OTHER
Change
0
Price
Not reported
Filing
03/18/2026
Type
OTHER
Enlivex Therapeutics Ltd.
ENLV • Biotechnology
$0.22
▼ -0.00 (-1.65%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$4.32M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Reasonable earnings multiple · 0.03Manageable debt level · 0Healthy liquidity · 193.24Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Oct 4, 2026, 12:05 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.22
Change-1.65%
Shares Out19.33M
Market Cap$4.32M
Enterprise Value$15.68M
Beta1.42
P/E0.00
P/B0.00
P/FCF-0.12
EV/EBITDA-0.79
EV/FCF-0.43
FCF Yield-852.19%
Price$0.22
Change-1.65%
Shares Out19.33M
Market Cap$4.32M
Enterprise Value$15.68M
Beta1.42
P/E0.00
P/B0.00
P/FCF-0.12
EV/EBITDA-0.79
EV/FCF-0.43
FCF Yield-852.19%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio193.24
Quick Ratio193.24
Target$15.00
Target Upside6718.18%
Target Median$15.00
Target Range15.00 - 15.00
Volume616.62K
Avg Volume266.33K
EPS Surprise-0.20
Investment DNA
How strong this company looks for long-term investors
48
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Reasonable earnings multiple · 0.03Manageable debt level · 0Healthy liquidity · 193.24Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 4 analyst votes · 2026-10-20
88/100
Bullish
Bullish
3
Hold
1
Bearish
0
Price Target
2026-10-04
Low
$15.00
Mean
$15.00
Median
$15.00
High
$15.00
Insider Transactions
Recent executive and insider activity
Havron Avraham
Transaction: 03/18/2026
OTHER
Change
+3,382
Price
$5.34
Filing
03/18/2026
Type
OTHER
Havron Avraham
Transaction: 03/18/2026
OTHER
Change
0
Price
Not reported
Filing
03/18/2026
Type
OTHER
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Galamidi Einat | OTHER | 0 | Not reported | 03/18/2026 | 03/18/2026 |
| Havron Avraham | OTHER | +3,382 | $5.34 | 03/18/2026 | 03/18/2026 |
| Havron Avraham | OTHER | 0 | Not reported | 03/18/2026 | 03/18/2026 |
| Pomerantz Roger | OTHER | +150,000 | $5.97 | 03/18/2026 | 03/18/2026 |
| Pomerantz Roger | OTHER | 0 | Not reported | 03/18/2026 | 03/18/2026 |
| NOVIK SHAI A | OTHER | 0 | Not reported | 03/18/2026 | 03/18/2026 |
| Hart Gili | OTHER | +3,382 | $5.34 | 03/18/2026 | 03/18/2026 |
| Hart Gili | OTHER | 0 | Not reported | 03/18/2026 | 03/18/2026 |
| Shlosberger Shachar | OTHER | 0 | Not reported | 03/18/2026 | 03/18/2026 |
| Hershkovitz Oren | OTHER | 0 | Not reported | 03/18/2026 | 03/18/2026 |
| Galamidi Einat | OTHER | +10,000 | $3.21 | 11/24/2025 | 03/18/2026 |
| Shlosberger Shachar | OTHER | +7,500 | $5.34 | 11/24/2025 | 03/18/2026 |
| Hershkovitz Oren | OTHER | +60,000 | $5.34 | 11/24/2025 | 03/18/2026 |
| NOVIK SHAI A | OTHER | +250,000 | $5.34 | 11/17/2025 | 03/18/2026 |
| NOVIK SHAI A | OTHER | +250,000 | $12.23 | 05/28/2024 | 03/18/2026 |
| Shlosberger Shachar | OTHER | +5,000 | $4.68 | 03/30/2024 | 03/18/2026 |
| Hershkovitz Oren | OTHER | +150,000 | $8.19 | 11/16/2023 | 03/18/2026 |
| NOVIK SHAI A | OTHER | +250,000 | $3.66 | 05/03/2023 | 03/18/2026 |
| Shlosberger Shachar | OTHER | +1,452 | $10.12 | 12/10/2022 | 03/18/2026 |
| NOVIK SHAI A | OTHER | +145,237 | $6.22 | 12/12/2021 | 03/18/2026 |